S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Ride These Railroad Stocks for Growth and Income
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
NASDAQ:ERAS

Erasca - ERAS Stock Forecast, Price & News

$4.04
+0.13 (+3.32%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.90
$4.11
50-Day Range
$3.75
$7.61
52-Week Range
$3.60
$12.80
Volume
1.00 million shs
Average Volume
922,131 shs
Market Capitalization
$494.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Erasca MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
11.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Erasca in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$2.57 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.20) to ($1.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

693rd out of 1,055 stocks

Pharmaceutical Preparations Industry

351st out of 519 stocks


ERAS stock logo

About Erasca (NASDAQ:ERAS) Stock

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

ERAS Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Erasca Chairman & CEO Makes $231K Stock Purchase
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Erasca to Present at Upcoming Investor Conferences
Peering Into Erasca's Recent Short Interest
See More Headlines
Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

ERAS Company Calendar

Last Earnings
11/09/2022
Today
1/28/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ERAS
Fax
N/A
Employees
123
Year Founded
N/A

Profitability

Net Income
$-122,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.77 per share

Miscellaneous

Free Float
76,476,000
Market Cap
$494.33 million
Optionable
Not Optionable
Beta
1.27

Key Executives

  • Dr. Jonathan E. Lim M.D. (Age 51)
    Co-Founder, Chairman & CEO
    Comp: $850.23k
  • Mr. Ebun S. Garner J.D. (Age 51)
    Esq., Gen. Counsel & Corp. Sec.
    Comp: $510.98k
  • Dr. Wei Lin M.D. (Age 53)
    Chief Medical Officer
    Comp: $1M
  • Dr. Michael D. Varney Ph.D. (Age 65)
    Chairman of R&D, Scientific Advisory Board Member and Director
    Comp: $78.38k
  • Dr. David M. Chacko M.D. (Age 39)
    Chief Financial Officer
  • Dr. Nik Chetwyn Ph.D.
    Sr. VP of Operations
  • Dr. Lisa Tesvich-Bonora Ph.D.
    Chief People Officer
  • Mr. Brian L. Baker CPA (Age 56)
    M.S., MS, CPA, Sr. VP of Fin.
  • Ms. Chandra D. Lovejoy (Age 52)
    Sr. VP of Regulatory Affairs
  • Dr. Robert Shoemaker Ph.D. (Age 42)
    Sr. VP of Research













ERAS Stock - Frequently Asked Questions

How have ERAS shares performed in 2023?

Erasca's stock was trading at $4.31 on January 1st, 2023. Since then, ERAS shares have decreased by 6.3% and is now trading at $4.04.
View the best growth stocks for 2023 here
.

Are investors shorting Erasca?

Erasca saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 8,060,000 shares, a decrease of 22.9% from the December 31st total of 10,460,000 shares. Based on an average daily volume of 1,070,000 shares, the short-interest ratio is presently 7.5 days. Approximately 11.6% of the shares of the company are sold short.
View Erasca's Short Interest
.

When is Erasca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our ERAS earnings forecast
.

How were Erasca's earnings last quarter?

Erasca, Inc. (NASDAQ:ERAS) released its earnings results on Wednesday, November, 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.02.

When did Erasca IPO?

(ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.

What is Erasca's stock symbol?

Erasca trades on the NASDAQ under the ticker symbol "ERAS."

How do I buy shares of Erasca?

Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Erasca's stock price today?

One share of ERAS stock can currently be purchased for approximately $4.04.

How much money does Erasca make?

Erasca (NASDAQ:ERAS) has a market capitalization of $494.34 million. The company earns $-122,760,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does Erasca have?

The company employs 123 workers across the globe.

How can I contact Erasca?

The official website for the company is www.erasca.com. The company can be reached via phone at 858-465-6511 or via email at ir@erasca.com.

This page (NASDAQ:ERAS) was last updated on 1/28/2023 by MarketBeat.com Staff